Volume | 560,675 |
|
|||||
News | - | ||||||
Day High | 3.37 | Low High |
|||||
Day Low | 3.02 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
BioAtla Inc | BCAB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.25 | 3.02 | 3.37 | 3.17 | 3.25 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
4,993 | 560,675 | US$ 3.17 | US$ 1,777,405 | - | 1.24 - 4.068 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:49:02 | 1 | US$ 3.17 | USD |
BioAtla Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
151.96M | 47.94M | - | 0 | -123.46M | -2.58 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioAtla News
Date | Time | Source | News Article |
---|---|---|---|
3/01/2024 | 15:19 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
2/21/2024 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
2/20/2024 | 15:22 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
2/20/2024 | 15:20 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
2/12/2024 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
2/01/2024 | 19:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
1/09/2024 | 08:01 | Edgar (US Regulatory) | Form 8-K - Current report |
1/08/2024 | 16:11 | Edgar (US Regulatory) | Form 8-K - Current report |
1/03/2024 | 19:17 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
12/19/2023 | 15:33 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
12/13/2023 | 07:31 | Edgar (US Regulatory) | Form 8-K - Current report |
12/04/2023 | 08:01 | Edgar (US Regulatory) | Form 8-K - Current report |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BCAB Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.54 | 3.5299 | 2.21 | 3.16 | 1,407,989 | 0.63 | 24.80% |
1 Month | 3.97 | 3.97 | 2.005 | 2.91 | 727,453 | -0.80 | -20.15% |
3 Months | 2.77 | 4.02 | 2.005 | 2.99 | 614,352 | 0.40 | 14.44% |
6 Months | 1.90 | 4.02 | 1.35 | 2.54 | 551,818 | 1.27 | 66.84% |
1 Year | 3.61 | 4.068 | 1.24 | 2.62 | 453,362 | -0.44 | -12.19% |
3 Years | 44.98 | 51.8299 | 1.24 | 7.71 | 525,820 | -41.81 | -92.95% |
5 Years | 30.55 | 76.63 | 1.24 | 10.33 | 496,399 | -27.38 | -89.62% |
BioAtla Description
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs. |